The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multicenter retrospective study to evaluate real-world clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) and brain metastasis treated with ipilimumab and nivolumab.
 
Landon Carter Brown
No Relationships to Disclose
 
Kunal Desai
Stock and Other Ownership Interests - Co-D Therapeutics
 
Chester Kao
No Relationships to Disclose
 
Emily Noelle Kinsey
No Relationships to Disclose
 
Patrick Healy
No Relationships to Disclose
 
Julie Kephart
No Relationships to Disclose
 
Michael Roger Harrison
Consulting or Advisory Role - Argos Therapeutics; AstraZeneca; Bayer; Bristol-Myers Squibb; Exelixis; Fujifilm; Genentech; Janssen Oncology; Pfizer; Sanofi
Speakers' Bureau - Exelixis; Genentech
Research Funding - Acerta Pharma (Inst); Argos Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Genentech (Inst); Medivation/Astellas (Inst); Merck (Inst); Pfizer (Inst)
 
Sundhar Ramalingam
No Relationships to Disclose
 
Andrew J. Armstrong
Honoraria - Dendreon; Janssen Oncology
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Janssen Biotech; Medivation; Pfizer; Sanofi
Speakers' Bureau - Bayer; Dendreon
Research Funding - Active Biotech (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Medivation (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture technology (Inst)
Travel, Accommodations, Expenses - Astellas Scientific and Medical Affairs Inc; Bayer; Dendreon; Janssen Biotech
 
Daniel J. George
Leadership - Capio BioSciences
Honoraria - Acceleron Pharma; American Association for Cancer Research; Axess Oncology; Bayer; EMD Serono; Exelixis; Janssen Oncology; Millennium Medical Publishing; OncLive; Pfizer; Sanofi; UroToday
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Exelixis; Genentech; Innocrin Pharma; Janssen; Merck Sharp & Dohme; Myovant Sciences; Pfizer; Sanofi
Speakers' Bureau - Bayer; Exelixis; Sanofi
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Dendreon (Inst); Exelixis (Inst); Innocrin Pharma (Inst); Janssen Oncology (Inst); Novartis (Inst); Pfizer (Inst); Sanofi/Aventis (Inst)
Travel, Accommodations, Expenses - Bayer; Exelixis; Janssen Oncology; Merck; Pfizer; Sanofi
 
Allison Martin
No Relationships to Disclose
 
Kimberly D. Allman
Consulting or Advisory Role - AstraZeneca; Bayer
Speakers' Bureau - Amgen; Exelis
 
Laura S. Wood
Consulting or Advisory Role - Eisai; EMD Serono; Merck
Speakers' Bureau - Bristol-Myers Squibb; Genentech/Roche; Merck; Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; EMD Serono; Genentech/Roche; Merck; Pfizer
 
Wei Wei
No Relationships to Disclose
 
Jorge A. Garcia
Consulting or Advisory Role - Bayer; Clovis Oncology; Eisai; Sanofi; Targeted Oncology
Speakers' Bureau - Bayer; Merck; Sanofi; Sanofi/Aventis
Research Funding - Genentech/Roche (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (I); Orion (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bayer; Clovis Oncology; Eisai; Janssen; Medivation/Astellas; Merck; Sanofi
 
Timothy D. Gilligan
Travel, Accommodations, Expenses - Dendreon
 
Shilpa Gupta
Stock and Other Ownership Interests - Nektar
Honoraria - AstraZeneca; Janssen Oncology
Consulting or Advisory Role - Exelixis; Genentech; Janssen Oncology; Merck
Speakers' Bureau - Bristol-Myers Squibb; Janssen Oncology
Research Funding - Astellas Medivation (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst)
 
Brian I. Rini
Leadership - MJH Life Sciences
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; Merck; Peloton Therapeutics; Pfizer; Roche/Genentech; Surface Oncology; synthorx
Research Funding - AstraZeneca/MedImmune (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; Pfizer
 
Moshe Chaim Ornstein
Consulting or Advisory Role - Eisai; Exelixis; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; Exelixis
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Exelixis
 
Tian Zhang
Leadership - Capio BioSciences (I)
Stock and Other Ownership Interests - Capio Biosciences (I)
Honoraria - Exelixis; Genentech/Roche
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Exelixis; Foundation Medicine; Genentech/Roche; Janssen; Merck; Pfizer; Pharmacyclics; Sanofi; Seagen
Speakers' Bureau - Exelixis; Genentech/Roche; Genomic Health; Sanofi/Aventis
Research Funding - Acerta Pharma (Inst); Janssen (Inst); Merck (Inst); Merrimack (Inst); Mirati Therapeutics (Inst); Novartis (Inst); OmniSeq (Inst); Personal Genome Diagnostics (Inst); Pfizer (Inst); Regeneron (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture by c-MET technology (Inst); Prochelators as Targeted Prodrugs for Prostate Cancer (Inst)
Travel, Accommodations, Expenses - Acerta Pharma; AstraZeneca; Genomic Health